Home › Companies › Keros Therapeutics, Inc. › 2025-2026

Keros Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
178Asset managers
842Fund votes
June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 4 items on Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026: 2 elected · 2 approved.

Material dissent

Elect Director: Jean-Jacques Bienaimé 66% of votes cast Elected Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Keros Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Keros Therapeutics, Inc.

These tallies are Keros Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Keros Therapeutics, Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Jean-Jacques Bienaimé	10,093,559	--	--	5,156,153	2,243,514	66%	Elected	—
Elect Director: Charles Newton	14,716,598	--	--	533,114	2,243,514	97%	Elected	—
2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026	16,708,279	783,953	994	--	--	96%	Approved	—
3. Advisory Vote on Executive Compensation	14,273,625	974,049	2,038	--	2,243,514	94%	Approved	—

Source: Keros Therapeutics, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.

How asset managers voted at the Keros Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 178 asset managers that disclosed a Keros Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Charles Newton

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 14,716,598WITHHELD: 533,114

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Charles Newton

Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles Newton”): 14,716,598 for, 533,114 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 5,779,670 for, 14,730 withheld, 1 abstained.

FOR

FOR: 5,779,670ABSTAIN: 1WITHHOLD: 14,730

Largest asset managers voting on “To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting ” at Keros Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	1,475,943	1	For
BlackRock	1,116,062	0	For
Fidelity	614,783	0	For
Federated Hermes	514,400	0	For
TIAA	260,385	0	For
Charles Schwab	179,991	0	For
Bridge Builder Trust	162,294	0	For
EA Series Trust	145,517	0	For
OLD WESTBURY FUNDS INC	143,853	0	For
Dimensional	123,808	0	For
Columbia Threadneedle	98,754	0	For
Nationwide	90,975	0	For
SEI	73,492	0	For
American Century	66,359	0	For
Equitable	62,765	0	For
Invesco	61,793	0	For
Principal Exchange-Traded Funds	58,899	0	For
BRIDGEWAY FUNDS INC	49,500	0	For
GuideStone	49,297	0	For
QUANTITATIVE MASTER SERIES LLC	47,584	0	For
Goldman Sachs	42,218	0	For
MFS	40,860	0	For
SEI Exchange Traded Funds	35,747	0	For
AQR	34,582	0	For
WisdomTree	31,176	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

2. Elect Director: Jean-Jacques Bienaimé

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD

FOR: 10,093,559WITHHELD: 5,156,153

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Jean-Jacques Bienaime

Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Jean-Jacques Bienaimé”): 10,093,559 for, 5,156,153 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 4,630,028 for, 1,164,362 withheld, 11 abstained.

FORWITHHOLD

FOR: 4,630,028ABSTAIN: 11WITHHOLD: 1,164,362

Largest asset managers voting on “To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting ” at Keros Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	1,475,234	11	699	For
BlackRock	1,116,062	0	0	For
Fidelity	614,783	0	0	For
Federated Hermes	514,400	0	0	For
TIAA	260,385	0	0	For
Charles Schwab	179,991	0	0	For
Bridge Builder Trust	162,294	0	0	For
EA Series Trust	0	0	145,517	Withhold
OLD WESTBURY FUNDS INC	0	0	143,853	Withhold
Dimensional	0	0	123,808	Withhold
Columbia Threadneedle	98,754	0	0	For
Nationwide	9,748	0	81,227	Mixed
SEI	0	0	73,492	Withhold
American Century	0	0	66,359	Withhold
Equitable	43,165	0	19,600	Mixed
Invesco	61,793	0	0	For
Principal Exchange-Traded Funds	0	0	58,899	Withhold
BRIDGEWAY FUNDS INC	0	0	49,500	Withhold
GuideStone	0	0	49,297	Withhold
QUANTITATIVE MASTER SERIES LLC	47,584	0	0	For
Goldman Sachs	0	0	42,218	Withhold
MFS	0	0	40,860	Withhold
SEI Exchange Traded Funds	0	0	35,747	Withhold
AQR	0	0	34,582	Withhold
WisdomTree	0	0	31,176	Withhold

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

3. 3. Advisory Vote on Executive Compensation

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%

FOR: 14,273,625AGAINST: 974,049

Details: description as filed, official tally, votes by 178 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.

Keros Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 14,273,625 for, 974,049 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN T” at Keros Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	1,475,943	1	For
BlackRock	1,116,062	0	For
Fidelity	614,783	0	For
Federated Hermes	514,400	0	For
TIAA	260,385	0	For
Charles Schwab	179,991	0	For
Bridge Builder Trust	162,294	0	For
EA Series Trust	145,517	0	For
OLD WESTBURY FUNDS INC	143,853	0	For
Dimensional	123,808	0	For
Columbia Threadneedle	98,754	0	For
Nationwide	90,975	0	For
SEI	73,492	0	For
American Century	0	66,359	Against
Equitable	62,765	0	For
Invesco	61,793	0	For
Principal Exchange-Traded Funds	58,899	0	For
BRIDGEWAY FUNDS INC	49,500	0	For
GuideStone	49,297	0	For
QUANTITATIVE MASTER SERIES LLC	47,584	0	For
Goldman Sachs	42,218	0	For
MFS	40,860	0	For
SEI Exchange Traded Funds	35,747	0	For
AQR	34,582	0	For
WisdomTree	31,176	0	For

Fund voting reports, all 58 managers: 5,711,225 for, 83,120 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 137 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN T” at Keros Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Nantahala Capital Management, LLC	1,326,947	0	For
BlackRock	923,549	0	For
ORBIMED ADVISORS LLC	759,155	0	For
Federated Hermes	680,516	0	For
GEODE CAPITAL MANAGEMENT, LLC	672,760	0	For
State Street	496,996	0	For
Madison Avenue Partners, LP	0	452,277	Against
DE Shaw	439,050	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	403,443	0	For
Two Sigma	326,214	0	For
BESSEMER INVESTMENT MANAGEMENT LLC	287,706	0	For
Nuveen	262,332	0	For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	244,638	0	For
AQR	237,506	0	For
Charles Schwab	180,024	0	For
Citadel	167,546	0	For
MACKENZIE FINANCIAL CORP	152,450	0	For
Vanguard	144,141	0	For
WELLS FARGO CLEARING SERVICES, LLC	140,000	0	For
ACADIAN ASSET MANAGEMENT LLC	123,252	0	For
Northern Trust	119,313	0	For
SEI	109,666	0	For
MELLON INVESTMENTS Corp	104,690	0	For
Point72	90,382	0	For
Invesco	86,714	0	For

Institutional-manager reports, all 137 managers: 9,771,432 for, 580,936 against. Showing the 25 largest; see all in the interactive database.

4. 2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the…

Official resultAUDIT-RELATEDReported outcome: Approved

96% Approved · of votes cast

FOR 96%

FOR: 16,708,279AGAINST: 783,953

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Keros Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026”): 16,708,279 for, 783,953 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 The Company's stockholders approved Proposal 2.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 5,794,400 for, 1 against.

FOR

FOR: 5,794,400AGAINST: 1

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEP” at Keros Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	1,475,943	1	For
BlackRock	1,116,062	0	For
Fidelity	614,783	0	For
Federated Hermes	514,400	0	For
TIAA	260,385	0	For
Charles Schwab	179,991	0	For
Bridge Builder Trust	162,294	0	For
EA Series Trust	145,517	0	For
OLD WESTBURY FUNDS INC	143,853	0	For
Dimensional	123,808	0	For
Columbia Threadneedle	98,754	0	For
Nationwide	90,975	0	For
SEI	73,492	0	For
American Century	66,359	0	For
Equitable	62,765	0	For
Invesco	61,793	0	For
Principal Exchange-Traded Funds	58,899	0	For
BRIDGEWAY FUNDS INC	49,500	0	For
GuideStone	49,297	0	For
QUANTITATIVE MASTER SERIES LLC	47,584	0	For
Goldman Sachs	42,218	0	For
MFS	40,860	0	For
SEI Exchange Traded Funds	35,747	0	For
AQR	34,582	0	For
WisdomTree	31,176	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Largest Keros Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,791,837 shares outstanding at the time of that meeting.

Fund voting reports: top Keros Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	7.46%
2	BlackRock	5.64%
3	Fidelity	3.11%
4	Federated Hermes	2.60%
5	TIAA	1.32%
6	Charles Schwab	0.91%
7	Bridge Builder Trust	0.82%
8	EA Series Trust	0.74%
9	OLD WESTBURY FUNDS INC	0.73%
10	Dimensional	0.63%

Institutional-manager reports: top Keros Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Nantahala Capital Management, LLC	6.70%
2	BlackRock	4.67%
3	ORBIMED ADVISORS LLC	3.84%
4	Federated Hermes	3.44%
5	GEODE CAPITAL MANAGEMENT, LLC	3.40%
6	State Street	2.51%
7	Madison Avenue Partners, LP	2.29%
8	DE Shaw	2.22%
9	JACOBS LEVY EQUITY MANAGEMENT, INC	2.04%
10	Two Sigma	1.65%

Reported Keros Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Keros Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	12.19%	13F
Jasbir Seehra, Ph.D.	9.46%	DEF14A
Vanguard Group	7.71%	13F
Nantahala Capital Management, LLC	6.87%	13G
Madison Avenue International LP	4.16%	13G
Geode Capital	3.44%	13F
State Street	2.84%	13F
Citadel Advisors	2.80%	13F
D.E. Shaw	2.57%	13F
Renaissance Technologies	2.29%	13F

Percentages above are of 19,791,837 shares outstanding, as reported by Keros Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Keros Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Keros Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 178 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 842 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS… — Keros Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Keros Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.

Keros Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.